Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > BUSINESS
BUSINESS
- Eisai Bags Up-to-US$5.76 Billion Lenvima Alliance with Merck
March 9, 2018
- Foreign Drug Makers Increased Market Share to Over 60% among Top 20 Makers in 2017
March 9, 2018
- Torii’s Futhan to Get 43.4% Price Cut in April, Urinorm 24.6%: Top 5 Product Survey
March 8, 2018
- Insomnia Drug Lemborexant Hits PIII Goals in Sleep Disorders: Eisai
March 8, 2018
- US FDA Approves Latuda for Pediatric Use in Bipolar I Depression: Sumitomo Dainippon
March 8, 2018
- Yoshikazu Aoki Named as New Asahi Kasei Pharma President
March 8, 2018
- Mid-Sized Japan Makers to Take Heaviest Hit from April Price Cut, Bigger Peers See Smaller Reductions: Jiho Survey
March 7, 2018
- Average NHI Price Reduction Rate of 12.8% for 3 Major Generic Makers: Jiho Tally
March 7, 2018
- Astellas, Tottori Univ. Pair Up to Develop, Commercialize Immunostimulating Gene Loading Oncolytic Virus
March 7, 2018
- Takeda Consumer Healthcare President Sugimoto to Step Down following 1 Year Stint since Firm’s Inception
March 7, 2018
- Alcon Pharma Reorganizes Marketing System to Boost Market Shares of Major Products including Lucentis
March 5, 2018
- Japan Ethical Drug Sales Slip 1.0% in 2017, Harvoni Drops Out of Top 10 List: IQVIA
March 2, 2018
- World’s 1st Commercial Manufacturing Plant for Allogeneic iPSC Therapies Completed: Sumitomo Dainippon
March 2, 2018
- Canaglu Launched in Taiwan: Mitsubishi Tanabe
March 2, 2018
- Galderma Completes Transfer of Japan Rozex Rights to Maruho
March 2, 2018
- Pfizer to Copromote Effexor SR with Sumitomo Dainippon
March 2, 2018
- Daiichi Sankyo US Subsidiary to Restructure Sales Unit with 280 Job Culls, Anticipating Launch of Oncology Agents
March 2, 2018
- Despite Solid Mainstays, Pfizer Japan’s FY2017 Sales Down 6.6% on LLPs
March 2, 2018
- Valixa’s Pediatric Indication Filed for CMV Infection in Organ Transplant
March 1, 2018
- Kaken Grants Rights for Psoriasis Drug Candidate to Valeant
March 1, 2018
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…